AUTHOR=Gong Mancheng , Song Erlin , Huang Guiying , Ni Wenjun , Dong Wenjing , Yuan Runqiang 

TITLE=Enhanced Expression of CNTD2/CCNP Predicts Poor Prognosis in Bladder Cancer Based on the GSE13507

JOURNAL=Frontiers in Genetics

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.579900

DOI=10.3389/fgene.2021.579900

ISSN=1664-8021

ABSTRACT=<p>Bladder cancer is one of the most common urogenital malignancies in the world, and there are no adequate prognostic indicators. <italic>CNTD2</italic> is one of the atypical cyclins, which may be related to the cell cycle and even the development of cancers. Early studies have shown that <italic>CNTD2</italic> is closely related to the occurrence and development of many malignant tumors. However, the mechanism of <italic>CNTD2</italic> in bladder cancer has not been reported. In our research, we explored the different expressions of <italic>CNTD2</italic> between 411 bladder cancers and 19 normal bladder tissues based on the TCGA dataset. <italic>CNTD2</italic>-related signaling pathways were identified through the GSEA. We analyzed the associations of <italic>CNTD2</italic> expression and bladder cancer progression and survival using GSE13507. Compared with 19 cases of normal bladder tissue, <italic>CNTD2</italic> gene expression was increased in 411 cases of bladder cancer. The high expression of <italic>CNTD2</italic> strongly correlated with grade (<italic>P</italic> &lt; 0.0001), T classification (<italic>P</italic> = 0.0001), N classification (<italic>P</italic> = 0.00011), M classification (<italic>P</italic> = 0.044), age (<italic>P</italic> = 0.027), and gender (<italic>P</italic> = 0.0012). Bladder cancer patients with high <italic>CNTD2</italic> expression had shorter overall survival (<italic>P</italic> &lt; 0.001). In the meantime, univariate and multivariate analyses showed that the increased expression of <italic>CNTD2</italic> was an independent factor for poor prognosis in bladder cancer patients (<italic>P</italic> &lt; 0.001 and <italic>P</italic> &lt; 0.001, respectively). <italic>CNTD2</italic> expression is closely related to bladder cancer progression, and the high expression of <italic>CNTD2</italic> may be an adverse biomarker in bladder cancer patients.</p>